Special Issue

Personalized Medicine in Benign and Malignant Adrenal Tumors

Message from the Guest Editors

Adrenocortical carcinoma is a rare endocrine tumor characterized by a grim prognosis, a strong propensity to recur after surgery, and a limited range of available therapeutic options. Therefore, great efforts are required to identify reliable prognostic factors, novel methods to secure early diagnosis and new markers for a timely detection of tumor recurrence following adrenalectomy. Given that the available medical therapies have limited efficacy and are quite toxic, the identification of new molecular targets that can be druggable and the development of innovative therapeutic agents is a definitive priority to improve patient care. In the meanwhile, studies focusing on the efficacy and safety of existing therapies, as well as on quality of life, should be promoted. This Special Issue will focus on all of these aspects, in particular on genetic, new "omics" markers, differential diagnosis, prognostic factors, as well as therapeutic approaches and their effects. Both original research and review articles are welcome.

Guest Editors

Prof. Dr. Massimo Terzolo

Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, TO, Italy

Dr. Soraya Puglisi

Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, 10043 Orbassano, Turin, Italy

Deadline for manuscript submissions

closed (15 January 2023)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/88133

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

